68Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy – diagnostic performance and impact on therapeutic decision-making

被引:0
作者
B. Grubmüller
P. Baltzer
D. D’Andrea
S. Korn
A. R. Haug
M. Hacker
K. H. Grubmüller
G. M. Goldner
W. Wadsak
S. Pfaff
J. Babich
C. Seitz
H. Fajkovic
M. Susani
P. Mazal
G. Kramer
S. F. Shariat
Markus Hartenbach
机构
[1] Medical University of Vienna,Department of Urology
[2] Medical University of Vienna,Division of General and Pediatric Radiology, Department of Biomedical Imaging and Image
[3] Medical University of Vienna,guided Therapy
[4] University Hospital Krems,Division of Nuclear Medicine, Department of Biomedical Imaging and Image
[5] Karl Landsteiner University of Health Sciences,guided Therapy
[6] Medical University of Vienna,Department of Urology and Andrology
[7] Center for Biomarker Research in Medicine,Department of Radiation Oncology
[8] CBmed GmbH,Division of Radiopharmaceutical Sciences, Department of Radiology
[9] Weill Medical College of Cornell University,Clinical Institute of Pathology
[10] Medical University of Vienna,Department of Urology
[11] University of Texas Southwestern,Department of Urology and Division of Medical Oncology
[12] Weill Medical College of Cornell University,undefined
来源
European Journal of Nuclear Medicine and Molecular Imaging | 2018年 / 45卷
关键词
Biochemical recurrence; Hybrid imaging; PET/CT; PET/MRI; Prostate cancer; PSMA ligand;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:235 / 242
页数:7
相关论文
共 102 条
[1]  
Ferlay J(2013)Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 Eur J Cancer 49 1374-1403
[2]  
Steliarova-Foucher E(2012)The impact of anatomical radical retropubic prostatectomy on cancer control: the 30-year anniversary J Urol 188 2219-2224
[3]  
Lortet-Tieulent J(2016)EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer Eur Urol 71 630-642
[4]  
Rosso S(2017)A framework for treatment decision making at prostate cancer recurrence Med Decis Mak 1 272989X17711913-943
[5]  
Coebergh JWW(2011)Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by (11C)choline positron emission tomography/computed tomography Eur Urol 60 935-309
[6]  
Comber H(2015)Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years Eur Urol 67 299-849
[7]  
Forman D(2015)Contemporary role of salvage lymphadenectomy in patients with recurrence following radical prostatectomy Eur Urol 67 839-2041
[8]  
Bray F(2007)Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy J Clin Oncol 25 2035-486
[9]  
Mullins JK(2014)Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy Eur Urol 66 479-1016
[10]  
Feng Z(2009)Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study Int J Radiat Oncol Biol Phys 73 1009-611